Grace Therapeutics, Stock Current Liabilities
| GRCE Stock | 3.66 0.30 8.93% |
Grace Therapeutics, fundamentals help investors to digest information that contributes to Grace Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Grace Stock. The fundamental analysis module provides a way to measure Grace Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Grace Therapeutics, stock.
The current year's Total Current Liabilities is expected to grow to about 2.7 M, whereas Non Current Liabilities Total is forecasted to decline to about 11 M. Grace | Current Liabilities |
Grace Therapeutics, Company Current Liabilities Analysis
Grace Therapeutics,'s Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Grace Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Grace Therapeutics, is extremely important. It helps to project a fair market value of Grace Stock properly, considering its historical fundamentals such as Current Liabilities. Since Grace Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Grace Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Grace Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Grace Current Liabilities Historical Pattern
Today, most investors in Grace Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Grace Therapeutics,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Grace Therapeutics, current liabilities as a starting point in their analysis.
Grace Therapeutics, Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Grace Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Grace Therapeutics, has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Grace Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Grace Therapeutics,'s direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Grace Therapeutics, could also be used in its relative valuation, which is a method of valuing Grace Therapeutics, by comparing valuation metrics of similar companies.Grace Therapeutics, is currently under evaluation in current liabilities category among its peers.
Grace Fundamentals
| Net Income | (12.85 M) | ||||
| Total Debt | 11.56 M | ||||
| Cash Flow From Operations | (12.33 M) | ||||
| Total Asset | 73.3 M | ||||
| Retained Earnings | (211.12 M) | ||||
| Working Capital | 22.33 M | ||||
| Net Asset | 73.3 M |
About Grace Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Grace Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Grace Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Grace Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Grace Therapeutics, Piotroski F Score and Grace Therapeutics, Altman Z Score analysis. For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grace Therapeutics,. If investors know Grace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grace Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Grace Therapeutics, is measured differently than its book value, which is the value of Grace that is recorded on the company's balance sheet. Investors also form their own opinion of Grace Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Grace Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grace Therapeutics,'s market value can be influenced by many factors that don't directly affect Grace Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grace Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grace Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.